25 January 2024 | News
Eli Lilly and Company, Santec Holdings Corporation participated in the funding round
image credit- shutterstock
PRISM BioLab, a Japan-based discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, has announced a 1.5 billion yen ($10.3 million) fundraise.
Funds will be used to refine PRISM's proprietary PepMetics chemistry platform, expand biology and screening capabilities and advance internal pipeline of PPI inhibitors.
According to Dai Takehara, CEO of PRISM BioLab, "The funds from this financing round will be used to integrate our PepMetics chemistry, biology and screening capabilities, to advance our internal pipeline, and to provide greater value to our existing and future pharma partners."
The company is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics targeting CBP/beta-catenin PPIs licensed to Eisai Co. and Ohara Pharmaceuticals Co. are in clinical development for cancer and liver disease, respectively.